Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	: 0.5							

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

1(c). Se	ee Instructio	n 10.																			
1. Name and Address of Reporting Person* Obenshain Andrew							2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE]								5. Re (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Obenshain Andrew							[BBOD]									Director			10% Ov	vner	
												Officer (give title below)			Other (s	specify					
(Last)	(3. Date of Earliest Transaction (Month/Day/Year)									- belov	below)								
C/O BLU	12/1	12/10/2024									President and CEO										
455 GRAND UNION BOULEVARD																					
		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable									
(Street)															Line) Form filed by One Reporting Person						
SOMER	VILLE 1	MA	02	2145												_	•		•		
																Perso	filed by Mo	re tnan	one Repo	orting	
(City)	(State)	(Z	ip)																	
			Table	I - No	n-Deriva	tive S	Secui	rities	Acc	uired	, Dis	posed of	, or B	Bene	ficial	ly Own	ed				
1. Title of S	Security (I	ion 2A. Deemed 3.						4. Securities								7. Nature					
					Date (Month/Day	//Year)	Execution Date, /Year) if any			Transaction Disposed Of (D Code (Instr. 5)			f (D) (In	(D) (Instr. 3, 4		Securi Benefi	cially	(D) or) or Indirect	of Indirect Beneficial	
						(Month/Day/Year)			8)					Owned Report	l Following ed	(I) (Ins		Ownership (Instr. 4)			
					Code	v	Amount	(A) or (D)		rice	Transaction(s) (Instr. 3 and 4)										
Common Stock 12/10/20							:024					971	D \$0		0.417	374,247			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
			Tuk	,ic ii -								convertib				OWIIC					
1. Title of	2.	3. Transaction 3A. D				4.		5. Num			6. Date Exercisable ar		7. Title and			Price of	9. Number		10.	11. Nature	
Derivative Security	Conversion or Exercise		n/Day/Year)	Execution Date, if any		Transa Code (ative	Expiration D (Month/Day/			Amount of Securities		s	erivative ecurity	derivative Securities	l F	Ownership Form:	of Indirect Beneficial	
(Instr. 3)	Price of Derivative			(Month	n/Day/Year)	8)		Securities Acquired						Underlying Derivative		nstr. 5)	Beneficially Owned		Direct (D) or Indirect	Ownership (Instr. 4)	
	Security							(A) or Disposed		Security 3 and 4)				nstr.		Following Reported		(I) (Instr. 4)	<u> </u>		
									of (D) (Instr. 3, 4 and 5)					3 and 4)			Transaction	n(s)			
																	(Instr. 4)				
								\neg						Amo	ount						
	Code										or Num	nber									
			Code	de V (A) (D)					Expiration Date	of Title Shares		.									
						Code V		(~)	(0)	Exercisable		Date	11116	Jilal	-53						

Explanation of Responses:

1. Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Remarks:

/s/ Sydney Gaylin, Attorney-

12/12/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

With respect to holdings of and transactions in securities issued by bluebird bio, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities
 Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule 144 ("Form 144"), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"); and
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this $23 \, \mathrm{rd}$ day of September, 2024.

/s/ Andrew Obenshain Andrew Obenshain

Schedule A

INDIVIDUALS APPOINTED AS ATTORNEY-IN-FACT, WITH FULL POWER OF SUBSTITUTION AND RESUBSTITUTION

- 1. Joseph Vittiglio
- 2. Sydney Gaylin